Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cytovance, NeuroFx Enter Development and Mfg. Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cytovance, NeuroFx Enter Development and Mfg. Pact

To deliver a robust process for cell-free therapy to treat neurological conditions

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cytovance Biologics, Inc. has partnered with NeuroFx to develop and manufacture stem cell derived, cell-free therapy for neurological conditions. NeuroFx has selected Cytovance to develop a therapeutic factor concentrate platform and program to deliver a robust development and manufacturing process.
 
Brian Johnstone Ph.D., director of R & D at NeuroFx, said, “Recognition of the critical function of mesenchymal stem cells’ (MSC) paracrine factors has prompted investigation into many different disease models of conditioned medium (CM) obtained from culturing MSC. Studies in rodent stroke models have validated the therapeutic potential of adipose stem/stromal cell (ASC) as well as MSC-derived therapeutic factors, demonstrating a similar effect as with cell delivery.”
 
John Conner, vice president of Manufacturing Operations at Cytovance Biologics, said, “We are excited to work together with NeuroFx to develop and manufacture a cell free therapeutic for neurological conditions based on a MSC-CM platform.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics